E K I Omogbai
Nigeria
Research Article
Levcromakalim (BRL38227): A Potassium Channel Activator Alters Some Biochemical Parameters in Streptozotocin- Induced Diabetic Rats
Author(s): O J Owolabi and E K I OmogbaiO J Owolabi and E K I Omogbai
Levcromakalim, a potassium channel activator reduces blood pressure and hence used in the management of hypertension, known to co-exist with diabetes mellitus; hence its effect on creatinine, urea and 24 hour urine output was investigated in streptozotocin- induced diabetic rats.
The rats were given levcromakalim (75 μg/kg/day) for 4 consecutive weeks, thereafter experimental diabetes mellitus was induced using streptozotocin (60 mg/kg).The rats were randomly placed into groups of 5 each and transferred to metabolic cages after treatment with glibenclamide (5 mg/kg), metformin (350 mg/kg) and insulin (5, 10, 20 and 40 i.u/kg).
The following parameters were investigated 24 hours after drug administration: plasma creatinine and urea, urine creatinine and urea, creatinine clearance and the 24 h urine volume.
The result.. View More»
